Bliwise D, Seidel W, Karacan I, Mitler M, Roth T, Zorick F, Dement W
Sleep. 1983;6(2):156-63. doi: 10.1093/sleep/6.2.156.
Sleep laboratory hypnotic medication trials typically determine efficacy by examining changes in polysomnographically recorded sleep. We introduce the use of daytime sleepiness, as assessed by the Multiple Sleep Latency Test (MSLT), as a criterion for daytime functioning in such trials. Two benzodiazepine hypnotics, triazolam (0.5 mg) and flurazepam (30 mg), with short and long half-lives respectively, were compared in a multicentered, double-blind crossover study. Results indicated these medications had virtually indistinguishable nocturnal effects, but differed dramatically during the day. Flurazepam decreased sleep latency on the MSLT, whereas triazolam did not. These results could indicate that daytime sleepiness is a concomitant effect of flurazepam.
睡眠实验室催眠药物试验通常通过检查多导睡眠图记录的睡眠变化来确定疗效。我们引入通过多次睡眠潜伏期试验(MSLT)评估的日间嗜睡作为此类试验中日间功能的一个标准。在一项多中心、双盲交叉研究中,对两种半衰期分别较短和较长的苯二氮䓬类催眠药三唑仑(0.5毫克)和氟西泮(30毫克)进行了比较。结果表明,这些药物的夜间效果几乎没有区别,但在白天却有显著差异。氟西泮缩短了MSLT的睡眠潜伏期,而三唑仑则没有。这些结果可能表明日间嗜睡是氟西泮的一种伴随效应。